Sanofi gets FDA approval for voice-guided epinephrine injector Auvi-Q
This article was originally published in Scrip
The US FDA has approved Sanofi's Auvi-Q, the first compact voice-guided epinephrine auto-injector for the emergency treatment of life-threatening allergic reactions in people at risk of anaphylaxis. The auto-injector has audio and visual cues that guide patients and caregivers step-by-step through the injection process.
You may also be interested in...
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.